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Cytokines in human renal interstitial fihrosis. H. Intrinsic Interleukin
(IL)-1 synthesis and IL-i-dependent production of IL-6 and IL-S by
cultured kidney fihrohlasts. We compared cytokine production from
transformed human fibroblast cell lines derived from either a kidney with
interstitial fibrosis or a normal kidney to that from primary human
foreskin fibroblasts. Fibrosis-derived as well as normal renal fibroblasts,
but not skin fibroblasts, spontaneously produced the chemokine, IL-8, and
the growth promoting cytokine, IL-6. Spontaneous IL-8 and IL-6 synthesis
by renal fibroblasts was dependent on the intrinsic release of IL-i, since
blocking IL-i receptors with IL-i receptor antagonist (IL-iRa) partially
inhibited the constitutive production of these cytokines. Both kidney cell
lines had detectable mRNA and protein for IL-ia and IL-1j3. Renal and
skin fibroblasts stimulated by picomolar concentrations of exogenous IL-i
or TNF-cs produced large amounts of IL-6 and IL-8, whereas nanomolar
concentrations of basic fibroblast growth factor did not. Fibrosis-derived
cells expressed less high affinity IL-i receptors (600 receptors/cell; K0 =
0.6 pM) compared to normal renal fibroblasts (1000 receptors/cell).
However, fibrosis-derived renal fibroblasts produce three- to fourfold
more IL-S and IL-6 in response to picomolar concentrations of IL-13
compared to cells derived from a normal kidney. As this enhanced
production is not due to increased numbers of IL-i receptors, we
speculate that post-receptor responsiveness to either endogenous or
exogenous IL-i is greater in fibrosis-derived renal fibroblasts than in cells
from normal kidneys.
There is increasing evidence that cytokines and growth factors
affect the onset as well as progression of renal inflammation [1—3].
Renal cells including glomerular mesangial cells and epithelial
cells are activated by the pro-inflammatory cytokines interleukin-i
(IL-i) [4] and tumor necrosis factor (TNF) [5] to express adhesion
molecules [6, 7], and to produce chemokines such as IL-S [8—10]
and monocyte chemotactic protein-i (MCP-1) [ii]. Furthermore,
proliferation of mesangial as well as epithelial cells is enhanced by
growth factors such as platelet-derived growth factor (PDGF) [12,
13], IL-6 [14], basic fibroblast growth factor (bFGF), insulin-like
growth factor-i (IGF-1), and epidermal growth factor (EGF) [15].
In contrast, mesangial cell growth is inhibited by transforming
growth factor (TGF)-/3 [16], In addition to their responsiveness to
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IL-i and TNF, glomerular mesangial cells synthesize these cyto-
kines [4, 5].
The pathogenic processes whereby renal function is lost in the
course of chronic glomerulonephritis (ON) is not fully under-
stood. In addition to the progression of the primary inflammatory
process in the glomerulus, the accompanying renal interstitial
inflammation is associated with the decline in kidney function
[17]. In fact, morphometric studies revealed that the decrease in
creatinine clearance in chronic ON correlates with the degree of
renal interstitial volume expansion [18—20]. Furthermore, the
number of infiltrating lymphocytes and macrophages in the inter-
stitium correlates well with the decline in kidney function [21, 22].
These data suggest that inflammatory processes in the renal
interstitium play an important role in the progression of primarily
glomerular disease to one of renal fibrosis and loss of kidney
function [23]. Tubular interstitial fibroblasts participate in this
process as demonstrated by studies using cultured cells from mice
or rabbits [24, 25]. Human fibroblasts derived from a kidney with
ON and interstitial fibrosis exhibit an increased rate of spontane-
ous proliferation when cultured in vitro [26]. This increased
proliferation depends, in part, on the intrinsic production of IL-i
(see preceeding paper in this issue).
In the present study we investigated whether human renal
fibroblasts produce the chemokine IL-S as well as the growth-
promoting cytokine IL-6. We studied whether IL-1/3, TNF-a, and
bFGF induced IL-6 and IL-8 production in two immortalized
human renal fibroblast cell lines, one established from a kidney
biopsy with ON and interstitial fibrosis and a control cell line
derived from a normal kidney. Primary human foreskin fibroblasts
were tested in comparison. Cells were studied for IL-i-dependent
cytokine production using the IL-i receptor antagonist (IL-iRa)
which blocks IL-i receptors without agonist activity [27].
Methods
Cytokines
Recombinant human IL-1f3 (10 U/mg) was a gift of Dr. Aldo
Tagliabue (Sclavo, Siena, Italy). Recombinant human IL-i recep-
tor antagonist (IL-iRa) was a gift of Dr. Daniel Tracey (Upjohn
Co., Kalamazoo, MI, USA) [27]. Recombinant human (TNF-a, 5
x iO U/mg) was obtained from Genentech Inc. (South San
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Francisco, CA, USA). Recombinant human bFGF was a gift from
Synergen Inc. (Boulder, CO, USA). Recombinant human IL-la
(2 X 108 U/mg) was a gift from Peter Lomedico (Hoffmann-
LaRoche, Nutley, NJ, USA). For binding assays, 5 jg of human
recombinant IL-la were labeled with 0.5 mCi of '25lodine using
the chioramine T method to a specific activity of 40 Ci/jLg [28].
Cell cultures
Human renal interstitial fibroblasts were obtained from the
meduliary part of a kidney biopsy with histologically proven GN
and interstitial fibrosis [26] or from the medulla of a normal
human donor kidney. Several one mm3 pieces of renal tissue from
the medulla were added to petri dishes covered with tissue culture
medium (DMEM; Sigma, St. Louis, MO, USA) supplemented
with 2 mrvi L-glutamine (Sigma), 10 mM Hepes (Sigma), 100 U/mi
penicillin, 100 tg/ml streptomycin (Gibco, Grand Island, NY,
USA), and 20% (voi/voi) fetal calf serum (FCS; HyCione Inc.,
Logan, UT, USA). Cells growing from the tissue specimens were
identified as epithelial cells and fibroblasts by morphologic criteria
and immunophenotyping [29, 30]. The mixed cultures were
treated with trypsin (0.05%)/EDTA (0.1%) (Gibco) and subcul-
tured in limiting dilutions in DMEM 20% FCS. Single cell type
colonies were surrounded by siliconized glass rings and
trypsinized. Fibroblast clones as identified by morphologic criteria
were subcultured in DMEM, 10% FCS.
Clones of these early passage human renal fibroblasts were
immortalized by transfection with the SV4O plasmid pSV3gpt [31].
Stable cell lines of these SV4O immortalized fibroblasts were
obtained by repeated subcloning of transfected cells [32]. The
renal fibroblast cell lines are comparable to the parental non-
transformed interstitial fibroblasts as indicated by similar mor-
phology, an unchanged expression pattern of collagens, fibronec-
tin, laminin and vimentin as well as the negative immunostaining
for cytokeratin, desmin and factor VIII in both cell lines [30, 32].
The two renal fibroblast cell lines (fibrosis-derived renal fibro-
blasts and normal renal fibroblasts) were maintained in RPMI
1640 (Sigma) containing L-glutamine, Hepes, antibiotics and 10%
(vol/vol) Serum Plus® (JRH Biosciences, Lenexa, KS, USA).
Renal fibroblasts were studied during passages 15 to 30.
Human skin fibroblasts were prepared from an infant foreskin
and grown to confluence in RPMI containing 10% Serum Plus in
75 cm2 tissue culture flasks (Costar, Cambridge, MA, USA). Skin
fibroblasts were subcultured in RPMI 1640 containing 10% Serum
Plus and studied during passages 5 to 20.
Fibroblast incubations
Fibroblasts were washed in PBS, tiypsinized (0.05% trypsin, 0.1%
EDTA) for two minutes at 37°C, diluted in RPMI containing 10%
Serum Plus to inactivate the trypsin and centrifuged for 10 minutes
at 250 x g. Cell pellets were resuspended in culture medium (RPMI
containing 10% Serum Plus) and quadruplicate samples of 200 1.d
aliquotes of cell suspension were added to 96-well flat bottom
microtiter plates (Costar). The cell number added to each well was
approximately 5,000 skin fibroblasts and approximately 25,000 renal
fibroblasts. After incubation for 24 hours, fibroblast supernatants
were replaced by 200 .tl of fresh culture medium alone (control), or
by culture medium containing various concentrations of IL-1(3,
TNF-a, or bFGF. Fibroblasts were then incubated for additional 24
hours and supernatants were removed for the measurement of IL-6
and IL-8 by radioimmunoassay.
In order to express the amounts of IL-8 and IL-6 produced as
a function of cell number, cell proliferation was determined in
each experiment by means of the XTT assay. In this proliferation
assay, the turnover of the tetrazolium salt XTT, 3,3'-[i-[(phe-
nylamino) carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)-ben-
zenesulfonic acid, hydrate, sodium salt (Polyscience, Inc. War-
rington, PA, USA) into its water soluble formazan product was
measured as an indicator of fibroblast proliferation [33]. There is
a strong linear correlation between results of the XTTassay and
number of cells counted in parallel fibroblast cultures after
trypsinization (details are in the preceeding paper, this issue).
Therefore, results of the XTT assay can be used to adjust for
relative changes in cell numbers in stimulated fibroblast cultures
compared to unstimulated controls. Results of the XTT assay
were plotted against cell counts to obtain standard curves for each
of the three fibroblast cell lines. Separate standard curves for each
cell line were necessary because the XTF turnover per cell was
approximately fivefold higher in skin fibroblasts than in both renal
fibroblast cell lines (see preceeding paper). The standard curves
were used to express the amount of cytokine produced per 5,000
skin fibroblasts or 25,000 renal fibroblasts, respectively.
In additional experiments, renal fibroblasts were incubated in
triplicate samples in 24 well plates in order to determine sponta-
neous as well as IL-i-induced IL-i synthesis. Total IL-ia and
IL-ip were measured in cell lysates of duplicate samples after
three freeze-thaw cycles by radioimmunoassay. Fibroblasts in the
corresponding third well of each sample were trypsinized and
counted in a Neubauer hemacytometer. The obtained cell counts
were then used to correct the measured amounts of IL-i for cell
numbers.
Radioimmunoassay for IL-1a, IL-1f3, IL-6 and IL-8
Cytokines were measured in fibroblast culture supernatants or
in total cell lysates after three freeze-thaw cycles by specific
radioimmunoassays (RIA). Each RIA was performed as described
previously [28, 34—36]. The Bolton-Hunter method [37] was used
to label IL-1f3. Bolton-Hunter labeled 125I-IL-6 was purchased
from New England Nuclear (Billerica, MA, USA). The concen-
tration of cytokine resulting in 95% of total binding of the 1251
labeled cytokine was defined as detection limit. The detection
limit of each RIA was between 40 and 80 pg/mi.
Determination of specific binding of IL-i to renal flbroblasts
Renal fibroblasts were grown to confluence in RPMI with 10%
Serum Plus in 6 well plates (Costar). Confluent cells (approxi-
mately 1.0 X 106 fibroblasts per well) were incubated with 80,000
cpm of 1251-IL-la (specific activity 40 j.tCi/g) in the presence or
absence of increasing concentrations of unlabeled IL-1/3 or IL-
iRa. Nonspecific binding to fibroblasts was determined in the
presence of 100 ng/ml of unlabeled IL-i13 or IL-iRa. Nonspecific
binding was 110 ii cpm and 170 20 cpm on fibrosis-derived
and normal renal fibroblasts, respectively.
Incubations were performed in binding buffer (RPMI contain-
ing 20 mri Hepes and 1% bovine serum albumin) for five hours at
6°C. Renal fibroblasts were then washed three times in binding
buffer (4°C) and subsequently lysed in 1 ml of lysing buffer (PBS
containing 1% SDS and 0.1 M NaOH). Radioactivity (counts per
minute, cpm) was counted in a gamma counter. Furthermore,
binding of various concentrations of 1251-IL-la to the two renal
fibroblast cell lines was studied. For each concentration of zJ
IL-la, specific binding was determined by subtracting the cpm in
the presence of 100 ng/ml of unlabeled IL-iRa (nonspecific
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binding) from that obtained in binding buffer alone (total bind-
ing). Specific binding curves were plotted and Scatchard plot
analysis was performed. The dissociation constant (KD = 1/-
slope) and receptor sites per cell were calculated for both cell
lines.
Due to low specific binding, background binding of 1251-IL-la
to the polystyrene culture plates was determined. Eighty thousand
cpm of 1251-IL-la were added to wells containing binding buffer
but no fibroblasts. There was no detectable recovery of labeled
IL-la from the polystyrene culture plates containing no cells.
RNA isolation and gene expression for IL-la and IL-i 13
Renal and skin fibroblasts were grown to confluence in RPM!
supplemented with 10% Serum Plus in 75 cm2 culture flasks.
Fibroblasts were washed in PBS and removed using rubber
policemen in 10 ml of PBS. The fibroblasts were centrifuged for 10
minutes at 250 X g and cell pellets were lysed in 4 M guanidine
isothiocyanate [38]. Total cellular RNA was isolated by centrifu-
gation through 5.7 M cesium chloride in 0.1 M EDTA. The RNA
pellet was resuspended in 200 d of distilled water containing
0.1% diethyl pyrocarbonate (DEPC-H20) and precipitated by
adding 2.5 volumes of 100% ethanol and sodium acetate (final
concentrations 0.1 M). After 24 hours at —70°C, the precipitate
was centrifuged in a microcentrifuge for 30 minutes at 4°C,
supernatants were decanted, RNA pellets were washed in 70%
ethanol, and again centrifuged for 10 minutes. Subsequently, the
70% ethanol was decanted and the pellets were dried in a speed
vacuum. RNA pellets were dissolved in 100 pA of DEPC-H20.
Total RNA was quantified by determination the ratio of UV light
absorbance at 260/280 A. Equal amounts of RNA (2.5, 1.25, 0.6,
and 0.3 g) per sample were transferred by vacuum suction to
nylon membranes (Hybond-N, Amersham Corp.) using a dot blot
minifold apparatus (Schleicher & Schuell, Inc., Keene, NH, USA)
and fixed by short wave UV radiation. Prehybridization, hybrid-
ization and autoradiography were performed using standard
techniques [38]. The IL-113 probe was a 1075-base pair fragment
of the full-length eDNA clone of the IL-113 precursor [39]
subcloned in pGEM2. The IL-la probe was a 432-base pair
fragment of the full length eDNA clone of the IL-la precursor
[40, 41]. The DNA was labeled with [a-32P]dCTP by use of a
random primer DNA labeling kit (Boehringer Mannheim, Ger-
many). As a RNA quantity control, samples were hybridized with
chicken 13-actin.
Statistical analysis
Fibroblast cultures were performed in quadruplicates in 96 well
plates or in duplicates in 24 well plates. For cytokine measure-
ments, the supernatants of quadruplicate and duplicate samples
were pooled. The "N" given in the Figure legends indicate the
number of independent experiments, each representing the aver-
age of quadruplicate or duplicate samples. Results of the cytokine
measurements are given as nanogram per cell number, mean
SEM, of the number of independent experiments. Significant
differences were assessed using one Factor ANOVA analysis.
Post-hoc method of data evaluation was Fisher's PLSD test.
Results
IL-i and TNF induce IL-8 and IL-6 production by renal fibroblasts
As shown in Figure 1, increasing concentrations of IL-1/3 and
TNF-a, but not bFGF, induced IL-8 production in fibrosis-derived
Cytokines, nglml
Fig. 1. IL-8 production by fibroblasts in response to JL-1!3, TNF-a, or
bFGF. Fibrosis-derived renal fibroblast (N = 8), normal renal fibroblast(N = 3) and skin fibroblast (N = 5) cultures were incubated for 24 hours
in tissue culture medium containing 10% Serum Plus with and without
IL-113, TNF-a, or bFGF indicated in ng/ml under the horizontal axis. IL-8
(mean SaM) in supernatants is expressed in nanogram per 25,000 renal
fibroblasts or in nanogram per 5,000 skin fibroblasts. < 0.05, < 0.01
compared to controls (10% Serum Plus only); n.d. = not done.
renal fibroblasts. A similar induction was observed in fibroblasts
derived from healthy kidney and skin. At 10 to 100 pg/ml (600 fM
to 6 pM), IL-l13 induced significant amounts of IL-8 (P < 0.05 and
P < 0.01, respectively). On a molar basis, IL-1J3 was approxi-
mately 10-fold more potent than TNF-a in inducing IL-8 in each
of the three fibroblast cell lines. Fibrosis-derived renal fibroblasts
produced three- to fourfold more IL-8 than normal renal fibro-
blasts. The differences in cytokine-induced IL-8 production per
25,000 renal fibroblasts was significant (P < 0.05) in response to
IL-1f3 (0.1 and 1 ng/ml) and high dose TNF-a (10 ng/ml).
The pattern of IL-1j3 and TNF-a-induced IL-6 production by
fibroblasts (Fig. 2) is similar to that for IL-8. Basic FGF does not
induce IL-6 above control levels, and IL-1/3 is approximately 10
times more potent than TNF-a in inducing IL-6 in each of the
fibroblast cultures. Compared to normal renal fibroblasts, fibrosis-
derived renal fibroblasts tended to produce more IL-6 per 25,000
cells.
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Fig. 2. IL-6 production by fibroblasts in response to IL-1J3, TNF-cv, or
bFGF. Under the conditions described in Figure 1, fibrosis-derived (N =
8) as well as normal renal fibroblast (N = 3) and skin fibroblast (N = 5)
cultures were stimulated for 24 hours with IL-1/3, TNF-a, or bFGF.
Cytokine-induced IL-6 in fibroblast supematants is depicted in nanogram
per 25,000 renal fibroblasts or in nanogram per 5,000 skin fibroblasts. The
mean SEM are shown. < 0.05, **p < 0.01 compared to controls; n.d.
= not done.
Spontaneous IL-8 and IL-6 production by renal fibroblasts is IL-i
dependent
In a second set of experiments, renal and skin fibroblasts were
incubated for various periods of time under conditions of IL-i
receptor blockade. To accomplish this, after trypsinization, each
fibroblast suspension was split into two aliquots, one containing
tissue culture medium alone (control) and the second containing
1 g/ml IL-iRa. As shown in Figures 3 and 4, fibrosis-derived as
well as normal renal fibroblasts spontaneously produce IL-8 and
IL-6 as detected in the fibroblast supernatants after 1, 3, 5, and 7
days of incubation. To compensate for the growth of cells during
these time periods, cytokine concentrations were corrected for
25,000 renal fibroblasts and 5,000 skin fibroblasts, respectively
(Methods). IL-8 and IL-6 production per 25,000 fibrosis-derived
renal fibroblasts or normal renal fibroblasts increased over time.
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Fig. 3. Effect of IL-iRa on spontaneous IL-8 production from fibroblasts.
Fibrosis-derived renal fibroblast (N = 6), normal renal fibroblast (N = 3),
or skin fibroblast (N = 4) cultures were incubated for 1, 3, 5, or 7 days in
media containing 10% Serum Plus without (closed circles) and with
IL-iRa at 1 Wml (closed triangles). IL-8 production in nanograms is
expressed per 25,000 renal fibroblasts and 5,000 skin fibroblasts, respec-
tively. Symbols represent the mean SEM; *P < 0.05, < 0.01
comparing controls (10% serum) to samples with IL-iRa at the same time.
However, this spontaneous IL-8 and IL-6 production was inhib-
ited in cultures containing IL-iRa. In contrast, spontaneous
production of IL-8 and IL-6 by skin fibroblasts did not increase
over time and was not affected by IL-iRa. Similar results were
observed when fibroblasts were grown in tissue culture medium
supplemented with 1% Serum Plus (data not shown).
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Fig. 4. Effect of IL-IRa on spontaneous IL-6 production from fibroblasts.
Fibrosis-derived (N = 6), normal renal fibroblast (N = 3) and skin
fibroblast (N = 4) cultures were incubated for 1, 3, 5, or 7 days under the
conditions described in Figure 3. Closed circles represent cultures in 10%
Serum Plus only; closed triangles depict 10% Serum Plus + IL-iRa at 1
mean SEM; < 0.05, < 0.01 comparing 10% serum to 10%
serum plus IL-iRa at the same time.
Fibroblasts were incubated for four days with or without IL-iRa
(Fig. 5 A, B). The effect of IL-iRa on spontaneous IL-8 and IL-6
production by renal fibroblasts was dose-dependent, reached
significance at 0.1 to 1 ng/ml (P < 0.05), and was maximal at 10
gIml. At this concentration, IL-iRa inhibition was 37 to 57% in
fibrosis-derived as well as normal renal fibroblasts. There was no
significant effect of IL-iRa on skin fibroblasts at any concentra-
tion of IL-iRa.
Gene expression and protein synthesis of IL-i /3 and IL-ia by
renal fibroblasts
Fibrosis-derived and normal renal fibroblasts spontaneously
**
expressed mRNA coding for IL-1/3 and IL-la (Fig. 6). Total RNA
was isolated from confluent fibroblast monolayers. For both renal
cell lines, this occurred after seven days and for skin fibroblasts
after 14 days of culture in 10% serum. As demonstrated by dot
blot analysis, normal and fibrosis-derived renal fibroblasts have
similar steady state levels of IL-i mRNA. For comparison, 5 .rg of
total RNA were extracted from skin fibroblasts. Skin fibroblasts
expressed similar levels of mRNA coding for IL-la but less IL-1f3
mRNA than both kidney fibroblasts cell lines.
We also measured synthesis of IL-i a and IL-1J3 in renal
fibroblasts. As IL-i concentrations in the culture supernatants
were at or below the detection limit of the RIAs (40 to 80 pg/mI),
fibroblasts were lysed by three freeze-thaw cycles and total IL-i
production (cell-associated plus secreted) was determined. There
was no detectable IL-la or IL-1f3 protein in skin fibroblasts (data
not shown). In contrast, both IL-i peptides were detectable in
renal cells, and spontaneous production of IL-la was twice as high
as that of IL-1/3 (P < 0.05) in both renal cell lines. Furthermore,
total IL-i synthesis was greater in normal renal fibroblasts (P <
0.05 for IL-1J3; P < 0,1 for IL-la) compared to fibrosis-derived
renal fibroblasts (Fig. 7). These data correspond to the higher
spontaneous, IL-i-dependent IL-6 and IL-8 production by normal
renal fibroblasts compared to fibrosis-derived cells (Figs. 3 and 4).
IL-i induces IL-i in renal fibroblasts
Normal as well as fibrosis-derived renal fibroblasts were grown
to confluence in 24-well culture plates and subsequently incubated
for three days in serum-free media in the presence and absence of
increasing amounts of IL-1/3. Fibroblasts were lysed by three
freeze-thaw cycles and total (cell-associated plus secreted) IL-la
was measured by RIA. As shown in Figure 8, IL-1/3-induced IL-la
increased dose-dependently. At 1 nglml IL-1/3, IL-la production
increased from 76 7 pg to 183 31 pg per 200,000 cells (P <
0.05) in fibrosis-derived renal fibroblasts and from 144 13 pg to
235 14 pg per 200,000 cells (P < 0.01) in normal renal
fibroblasts. IL-la production by both renal cell lines increased
further in response to 10 and 100 ng/ml of IL-1/3.
Determination of specific IL-i binding sites on renal fibroblasts
The specific binding of 25I-IL-1a was determined in the two
renal cell lines. Each renal fibroblast cell line specifically bound
approximately 0.1% of the total label as demonstrated by the
binding curves (Fig. 9A) and Scatchard plot analysis (Fig. 9B).
Based on these data, the calculated dissociation constant (KD) for
normal renal fibroblasts and fibrosis-derived renal fibroblasts were
0.53 M and 0.66 p, respectively. The calculated number of
receptor sites per cell were 1,080 per normal renal fibroblast and
600 receptors per fibrosis-derived renal fibroblast. When taken
together, these data demonstrate that both renal fibroblast cell
lines express relatively few IL-i receptor sites per cell with high
affinity. As shown in Figure 10 A and B, the binding of IL-la to
fibrosis-derived or normal renal fibroblasts was inhibited by either
IL-iRa or IL-1/3. Inhibition of binding by IL-iRa was similar to
that by IL-1/3.
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Discussion
Human renal interstitial fibroblasts are likely to participate in
the pathogenesis of interstitial inflammation with fibrosis due to
proliferation and matrix production [231. The present study
provides evidence that renal fibroblasts are also a source of the
chemokine IL-8 as well as the growth-promoting cytokine IL-6.
Cultured renal fibroblasts spontaneously produce IL-8 and IL-6
and approximately 50% of this spontaneous production is depen-
dent on the intrinsic synthesis of IL-i. The spontaneous produc-
tion of IL-6 and IL-8 is higher in renal fibroblasts derived from a
normal kidney than in those obtained from a kidney with glomer-
ulonephritis and interstitial fibrosis. This increased synthesis is
associated with an increased spontaneous production of IL-la
and IL-113. In addition, IL-1p induced more IL-la in normal than
in fibrosis-derived renal fibroblasts. There is also a higher expres-
sion of specific IL-i binding sites on normal renal fibroblasts
compared to fibrosis-derived renal fibroblasts. As both renal
fibroblast cell lines similarly express the genes for IL-la and 13,
these data suggest that post-transcriptional events involving trans-
lation and processing of IL-i as well as expression of IL-i
receptors are downregulated in unstimulated fibrosis-derived fi-
broblasts compared to normal renal cells.
Although mRNA coding for IL-ia and 13 in primary skin
fibroblasts was observed, IL-i synthesis, however, was not de-
tected in these cells. These data are in agreement with a study by
Elias et al who described accumulation of IL-1/3 mRNA in IL-i (a
or 13) stimulated fibroblasts without translation into the IL-i
precursor [423. The authors concluded that IL-i production in
human lung fibroblasts is inhibited on a post-transcriptional level
[42]. According to our data, a similar post-transcriptional regula-
tion seems to occur in skin fibroblasts. In contrast, post-transcrip-
tional blockade of IL-i synthesis is not complete in the two renal
fibroblast cell lines tested in this study. IL-i-producing fibroblasts
may be due to organ specificity or secondary to the SV4O
transformation.
The number of specific IL-i binding sites on the two trans-
formed fibroblast cell lines of kidney origin was relatively small
with 600 to 1080 sites per cell. Of the two IL-i receptors, the type
I IL-i receptor accounts for IL-i binding to renal fibroblasts
because of its high affinity for IL-la as indicated by the KD of
approximately 1 X 10— 12 M. This high affinity is comparable to
that of IL-i receptors determined on human lung fibroblasts [43],
or normal human skin fibroblasts [44]. The number of binding
sites per cell, however, was higher with 1,600 per cell on skin
fibroblasts [44] and 3,000 per cell on lung fibroblasts [43].
Explanations for the expression of low number of receptors on
fibrosis-derived renal fibroblasts remain speculative. However, it
is possible that there are reduced numbers of unoccupied recep-
tors because these cells spontaneously produce IL-i. It has been
shown that receptor occupancy of less than 5% by IL-i is able to
downregulate the surface expression of the IL-i receptor type I
[45]. Therefore, the reduced expression of IL-i receptors on
fibrosis-derived renal fibroblasts may reflect chronic stimulation
of these cells by IL-i itself.
The production of IL-6 and IL-8 in response to picogram
concentrations of exogenous IL-1p was higher in fibrosis-derived
than in normal renal fibroblasts. According to our data, this
enhanced responsiveness is neither explained by differences in the
number of IL-i binding sites nor by a change in the affinity of the
IL-i receptor on fibrosis-derived fibroblasts. We speculate that
signal transduction pathways for IL-i-induced IL-6 and IL-8
production are more efficient in fibrosis-derived renal fibroblasts
than in cells derived from normal kidneys.
Compared to primary skin fibroblasts, the pattern of IL-8 and
IL-6 production in response to exogenous IL-113 and TNF-a was
similar in the two renal fibroblast cell lines. On a molar bases,
IL-1/3 was approximately 10-fold more potent than TNF-a in
inducing IL-6 and IL-8 in each cell line. These results are in
agreement with previous studies using rat kidney fibroblasts [46]
and fibroblasts derived from human skin [47, 48], synovial tissue
[49, 50] or lung [51—53]. Recent data further suggest that IL-i and
TNF-a may act synergistically in inducing IL-8 production in
fibroblasts [54]. In contrast, bFGF did not induce IL-6 or IL-S
above background in the three cell lines and did not enhance IL-i
or TNF-a-induced IL-8 or IL-6 production (data not shown).
These data support the concept that IL-8 as well as IL-6 produc-
tion by fibroblasts, including renal fibroblasts, depends on the
stimulation by pro-inflammatory cytokines such as IL-i and
TNF-a rather than on growth factors.
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Fibrosis-derived renal fibroblasts (closed
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squares), and skin fibroblasts (closed triangles)
were incubated for 5 days in media containing
10% Serum Plus in the absence or presence of
increasing concentrations of IL-iRa. IL-8 and
IL-6 production in the presence of IL-iRa are
expressed as the per cent of that from control
(cells in 10% Serum Plus only). Data represent
the mean SEM of 3 separate experiments.
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Fig. 7. Spontaneous IL-ia and IL-lf3productionfromfibroblasts. Fibrosis-
derived renal fibroblast (hatched bars) and normal renal fibroblast (open
bars) cultures were incubation for 5 days in media containing 1% Serum
Plus. Cells were lysed by three freeze-thaw cycles and total production
(cell-associated plus secreted) of IL-la and IL-1f3 was measured by
specific RIA. IL-i production is expressed in picogram per 200,000
fibroblasts. The bars represent the mean SCM of 4 independent
experiments done in duplicates; *P < 0.05 as indicated by horizontal lines.
The difference in IL-la production was not significant (P < 0.1).
Fig. 6. Gene expression for human IL-la and !L-113. Total RNA was
extracted from skin fibroblasts (lane 1, 5 g only), fibrosis-derived (lanes
2 to 4) as well as normal renal fibroblasts (lanes 5 to 7) after reaching
confluence (after 7 and 14 days for renal and skin cells, respectively). RNA
for renal fibroblasts were diluted (5, 2.5, 1.25, 0.62, and 0.31 jsg/well) and
the membrane hybridized with eDNA probes coding for human IL-la,
human IL-1f3, and 13-actin as an RNA control.
In the preceeding paper, we described the spontaneous prolif-
eration of fibrosis-derived renal fibroblasts but not that of normal
renal fibroblasts was IL-i-dependent because IL-i receptor block-
ade using IL-IRa reduced growth. We concluded from those
results that renal fibroblasts derived from diseased kidneys are
different from normal renal fibroblasts in that the former produce
IL-i as a paracrine growth factor. We now demonstrated that both
kidney fibroblast cell lines spontaneously produce IL-ia and
IL-1j3, and that this endogenous IL-i induces IL-6 production via
an IL-i paracrine ioop. The fact that the spontaneous prolifera-
tion of normal renal fibroblasts was not inhibited by IL-iRa,
although these cells produce IL-i, suggests that signal transduc-
lL-1, ng/ml
Fig. 8. IL-i induces IL-I in renal fibroblasts. Fibroblasts derived from
kidney fibrosis and normal kidney were grown to confluence in 24 well
plates and incubated for 3 days in serum-free media in the absence and
presence of the indicated amounts of IL-1f3. Total IL-la production is
expressed in picogram per 200,000 fibroblasts. The bars represent the
mean SCM of 4 experiments; *p < 0.05, * < 0.01 compared to control
(no IL-i).
tion pathways for IL-i-induced IL-6 are different and indepen-
dently regulated from those of IL-i-induced proliferation [55, 561.
Infiltrating leukocytes including granulocytes, monocyte/macro-
phages and lymphocytes play a critical role in several models of
renal disease [57, 58]. Leukocytes are attracted by the chemokines
including IL-8 and MCP-l which are produced by intrinsic cells at
the site of inflammation [59]. Although the chemotactic activity of
IL-8 was originally described for neutrophils [60, 61], low concen-
trations of IL-8 are chemoattractant for lymphocytes in vivo [621.
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Fig. 9. Specific binding of IL-I to renal fibroblasts. Renal fibroblasts were
incubated for 5 hours at 6°C in binding buffer containing increasing
amounts of '251-IL-ln in the presence (nonspecific binding) or absence
(total binding) of 100 nglml IL-iRa. Specific binding (total-nonspecific) is
shown in A. The Scatchard plot (B) shows reduced binding sites on
fibrosis-derived compared to normal renal fibroblasts. The K0 was similar
with 0.53 pmol for normal renal fibroblasts and 0.66 pmol for fibrosis-
derived renal fibroblasts. The mean of duplicate data of 1 out of 3 similar
experiments are shown.
This may be important with respect to the renal interstitial
infiltrate which contains predominantly lymphocytes and macro-
phages and very few granulocytes [21, 22].
Cultured human glomerular mesangial cells produce IL-8 [8]
and MCP-1 [11], and it has been demonstrated that the release of
these chemotactic factors from mesangial cells was inhibited by
IL-iRa [63, 64]. In the present paper we demonstrate that a
similar mechanism is present in renal interstitial fibroblasts. These
data suggest that in renal inflammation, renal cells including
mesangial cells and interstitial fibroblasts release chemoattractant
IL-1, fmol
Fig. 10. Displacement of bound '251-IL-la by unlabeled IL-1J3 and IL-iRa.
Renal fibroblasts were incubated for 5 hours at 6°C in binding buffer
containing 80,000 cpm of '251-IL-la per 1 x 106 cells in the presence or
absence of increasing concentrations of unlabeled IL-iRa (A) or unla-
beled IL-113 (B).
activity with the consequence of leukocyte infiltration which
depends on the intrinsic production of IL-i.
Like spontaneous IL-8 production, IL-6 is inhibited by IL-iRa
in mesangial cells [63], and in the present study we observed this
dependency in renal fibroblasts. Although IL-6 has been initially
described to enhance proliferation of mesangial cells in culture
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[14], the growth-promoting activity of IL-6 is controversial in that
in studies exogenous IL-6 has an inhibitory effect on mesangial
cell proliferation [65]. Furthermore, using a mouse model of IgA
nephropathy, Montinaro et al showed that administration of IL-6
in combination with IL-i, but not IL-6 alone, induced hypercel-
lularity in the glomerulus [66]. Although both renal fibroblast cell
lines produce IL-6, it remains to be elucidated whether these cells
use IL-6 as a growth factor.
In summaly, human renal interstitial fibroblasts in culture
spontaneously produce IL-6 and IL-8. This spontaneous synthesis
of growth promoting as well as chemotactic activity depends, in
part, on the intrinsic production of IL-i. The paracrine IL-i loop
promotes spontaneous proliferation as well as IL-8 and IL-6
production in fibrosis-derived renal fibroblasts. Therefore, IL-i
synthesis by interstitial fibroblasts is likely to contribute to the
development of interstitial fibrosis in the course of chronic
inflammatory kidney diseases. It remains to be established
whether a down-regulation of renal-fibroblast IL-i production, for
example by IL-iRa, could be beneficial to prevent interstitial
inflammation with subsequent fibrosis.
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